Insights from nanomedicine into chloroquine efficacy against COVID-19.
Identifieur interne : 001A55 ( Main/Curation ); précédent : 001A54; suivant : 001A56Insights from nanomedicine into chloroquine efficacy against COVID-19.
Auteurs : Tony Y. Hu [États-Unis] ; Matthew Frieman [États-Unis] ; Joy Wolfram [États-Unis]Source :
- Nature nanotechnology [ 1748-3395 ] ; 2020.
Descripteurs français
- KwdFr :
- Antiviraux (pharmacocinétique), Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Betacoronavirus (MeSH), Chloroquine (pharmacocinétique), Chloroquine (pharmacologie), Chloroquine (usage thérapeutique), Concentration en ions d'hydrogène (MeSH), Endocytose (effets des médicaments et des substances chimiques), Glycoprotéine de spicule des coronavirus (effets des médicaments et des substances chimiques), Glycoprotéine de spicule des coronavirus (métabolisme), Humains (MeSH), Hydroxychloroquine (pharmacocinétique), Hydroxychloroquine (pharmacologie), Hydroxychloroquine (usage thérapeutique), Infections à coronavirus (traitement médicamenteux), Inflammation (MeSH), Nanomédecine (MeSH), Nanoparticules (MeSH), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux), Réplication virale (effets des médicaments et des substances chimiques), Virion (effets des médicaments et des substances chimiques).
- MESH :
- effets des médicaments et des substances chimiques : Endocytose, Glycoprotéine de spicule des coronavirus, Réplication virale, Virion.
- métabolisme : Glycoprotéine de spicule des coronavirus.
- pharmacocinétique : Antiviraux, Chloroquine, Hydroxychloroquine.
- pharmacologie : Antiviraux, Chloroquine, Hydroxychloroquine.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Antiviraux, Chloroquine, Hydroxychloroquine.
- Betacoronavirus, Concentration en ions d'hydrogène, Humains, Inflammation, Nanomédecine, Nanoparticules, Pandémies.
English descriptors
- KwdEn :
- Antiviral Agents (pharmacokinetics), Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Chloroquine (pharmacokinetics), Chloroquine (pharmacology), Chloroquine (therapeutic use), Coronavirus Infections (drug therapy), Endocytosis (drug effects), Humans (MeSH), Hydrogen-Ion Concentration (MeSH), Hydroxychloroquine (pharmacokinetics), Hydroxychloroquine (pharmacology), Hydroxychloroquine (therapeutic use), Inflammation (MeSH), Nanomedicine (MeSH), Nanoparticles (MeSH), Pandemics (MeSH), Pneumonia, Viral (drug therapy), SARS-CoV-2 (MeSH), Spike Glycoprotein, Coronavirus (drug effects), Spike Glycoprotein, Coronavirus (metabolism), Virion (drug effects), Virus Replication (drug effects).
- MESH :
- chemical , drug effects : Spike Glycoprotein, Coronavirus.
- chemical , metabolism : Spike Glycoprotein, Coronavirus.
- chemical , pharmacokinetics : Antiviral Agents, Chloroquine, Hydroxychloroquine.
- chemical , pharmacology : Antiviral Agents, Chloroquine, Hydroxychloroquine.
- chemical , therapeutic use : Antiviral Agents, Chloroquine, Hydroxychloroquine.
- drug effects : Endocytosis, Virion, Virus Replication.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, COVID-19, Humans, Hydrogen-Ion Concentration, Inflammation, Nanomedicine, Nanoparticles, Pandemics, SARS-CoV-2.
DOI: 10.1038/s41565-020-0674-9
PubMed: 32203437
PubMed Central: PMC7094976
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001A55
Links to Exploration step
pubmed:32203437Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Insights from nanomedicine into chloroquine efficacy against COVID-19.</title>
<author><name sortKey="Hu, Tony Y" sort="Hu, Tony Y" uniqKey="Hu T" first="Tony Y" last="Hu">Tony Y. Hu</name>
<affiliation wicri:level="1"><nlm:affiliation>Center for Cellular and Molecular Diagnostics, Department of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, LA, USA. tonyhu@tulane.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Cellular and Molecular Diagnostics, Department of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, LA</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Frieman, Matthew" sort="Frieman, Matthew" uniqKey="Frieman M" first="Matthew" last="Frieman">Matthew Frieman</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA. mfrieman@som.umaryland.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wolfram, Joy" sort="Wolfram, Joy" uniqKey="Wolfram J" first="Joy" last="Wolfram">Joy Wolfram</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biochemistry and Molecular Biology, Mayo Clinic, Jacksonville, FL, USA. wolfram.joy@mayo.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biochemistry and Molecular Biology, Mayo Clinic, Jacksonville, FL</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Physiology and Biomedical Engineering, Mayo Clinic, Jacksonville, FL, USA. wolfram.joy@mayo.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Physiology and Biomedical Engineering, Mayo Clinic, Jacksonville, FL</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Transplantation, Mayo Clinic, Jacksonville, FL, USA. wolfram.joy@mayo.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Transplantation, Mayo Clinic, Jacksonville, FL</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA. wolfram.joy@mayo.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32203437</idno>
<idno type="pmid">32203437</idno>
<idno type="doi">10.1038/s41565-020-0674-9</idno>
<idno type="pmc">PMC7094976</idno>
<idno type="wicri:Area/Main/Corpus">001A55</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001A55</idno>
<idno type="wicri:Area/Main/Curation">001A55</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001A55</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Insights from nanomedicine into chloroquine efficacy against COVID-19.</title>
<author><name sortKey="Hu, Tony Y" sort="Hu, Tony Y" uniqKey="Hu T" first="Tony Y" last="Hu">Tony Y. Hu</name>
<affiliation wicri:level="1"><nlm:affiliation>Center for Cellular and Molecular Diagnostics, Department of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, LA, USA. tonyhu@tulane.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Cellular and Molecular Diagnostics, Department of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, LA</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Frieman, Matthew" sort="Frieman, Matthew" uniqKey="Frieman M" first="Matthew" last="Frieman">Matthew Frieman</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA. mfrieman@som.umaryland.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wolfram, Joy" sort="Wolfram, Joy" uniqKey="Wolfram J" first="Joy" last="Wolfram">Joy Wolfram</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biochemistry and Molecular Biology, Mayo Clinic, Jacksonville, FL, USA. wolfram.joy@mayo.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biochemistry and Molecular Biology, Mayo Clinic, Jacksonville, FL</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Physiology and Biomedical Engineering, Mayo Clinic, Jacksonville, FL, USA. wolfram.joy@mayo.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Physiology and Biomedical Engineering, Mayo Clinic, Jacksonville, FL</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Transplantation, Mayo Clinic, Jacksonville, FL, USA. wolfram.joy@mayo.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Transplantation, Mayo Clinic, Jacksonville, FL</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA. wolfram.joy@mayo.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Nature nanotechnology</title>
<idno type="eISSN">1748-3395</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (pharmacokinetics)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Betacoronavirus (MeSH)</term>
<term>COVID-19 (MeSH)</term>
<term>Chloroquine (pharmacokinetics)</term>
<term>Chloroquine (pharmacology)</term>
<term>Chloroquine (therapeutic use)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Endocytosis (drug effects)</term>
<term>Humans (MeSH)</term>
<term>Hydrogen-Ion Concentration (MeSH)</term>
<term>Hydroxychloroquine (pharmacokinetics)</term>
<term>Hydroxychloroquine (pharmacology)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Inflammation (MeSH)</term>
<term>Nanomedicine (MeSH)</term>
<term>Nanoparticles (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Spike Glycoprotein, Coronavirus (drug effects)</term>
<term>Spike Glycoprotein, Coronavirus (metabolism)</term>
<term>Virion (drug effects)</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (pharmacocinétique)</term>
<term>Antiviraux (pharmacologie)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Chloroquine (pharmacocinétique)</term>
<term>Chloroquine (pharmacologie)</term>
<term>Chloroquine (usage thérapeutique)</term>
<term>Concentration en ions d'hydrogène (MeSH)</term>
<term>Endocytose (effets des médicaments et des substances chimiques)</term>
<term>Glycoprotéine de spicule des coronavirus (effets des médicaments et des substances chimiques)</term>
<term>Glycoprotéine de spicule des coronavirus (métabolisme)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (pharmacocinétique)</term>
<term>Hydroxychloroquine (pharmacologie)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Inflammation (MeSH)</term>
<term>Nanomédecine (MeSH)</term>
<term>Nanoparticules (MeSH)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Réplication virale (effets des médicaments et des substances chimiques)</term>
<term>Virion (effets des médicaments et des substances chimiques)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Spike Glycoprotein, Coronavirus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Spike Glycoprotein, Coronavirus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiviral Agents</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Endocytosis</term>
<term>Virion</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Endocytose</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Réplication virale</term>
<term>Virion</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Glycoprotéine de spicule des coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Antiviraux</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term>
<term>COVID-19</term>
<term>Humans</term>
<term>Hydrogen-Ion Concentration</term>
<term>Inflammation</term>
<term>Nanomedicine</term>
<term>Nanoparticles</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Betacoronavirus</term>
<term>Concentration en ions d'hydrogène</term>
<term>Humains</term>
<term>Inflammation</term>
<term>Nanomédecine</term>
<term>Nanoparticules</term>
<term>Pandémies</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32203437</PMID>
<DateCompleted><Year>2020</Year>
<Month>04</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1748-3395</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>15</Volume>
<Issue>4</Issue>
<PubDate><Year>2020</Year>
<Month>04</Month>
</PubDate>
</JournalIssue>
<Title>Nature nanotechnology</Title>
<ISOAbbreviation>Nat Nanotechnol</ISOAbbreviation>
</Journal>
<ArticleTitle>Insights from nanomedicine into chloroquine efficacy against COVID-19.</ArticleTitle>
<Pagination><MedlinePgn>247-249</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/s41565-020-0674-9</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Hu</LastName>
<ForeName>Tony Y</ForeName>
<Initials>TY</Initials>
<AffiliationInfo><Affiliation>Center for Cellular and Molecular Diagnostics, Department of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, LA, USA. tonyhu@tulane.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y" EqualContrib="Y"><LastName>Frieman</LastName>
<ForeName>Matthew</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA. mfrieman@som.umaryland.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wolfram</LastName>
<ForeName>Joy</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Mayo Clinic, Jacksonville, FL, USA. wolfram.joy@mayo.edu.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Physiology and Biomedical Engineering, Mayo Clinic, Jacksonville, FL, USA. wolfram.joy@mayo.edu.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Transplantation, Mayo Clinic, Jacksonville, FL, USA. wolfram.joy@mayo.edu.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA. wolfram.joy@mayo.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R21AI52318</GrantID>
<Agency>U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency>
<Country>International</Country>
</Grant>
<Grant><GrantID>R21EB026347</GrantID>
<Agency>U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (NIBIB)</Agency>
<Country>International</Country>
</Grant>
<Grant><GrantID>DODW8IXWH1910926</GrantID>
<Agency>U.S. Department of Defense (United States Department of Defense)</Agency>
<Country>International</Country>
</Grant>
<Grant><GrantID>R21 EB026347</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01AI113725</GrantID>
<Agency>U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency>
<Country>International</Country>
</Grant>
<Grant><GrantID>R01 AI113725</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 HD090927</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01AI122932</GrantID>
<Agency>U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency>
<Country>International</Country>
</Grant>
<Grant><GrantID>R21 AI152318</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 AI122932</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R21AI126361</GrantID>
<Agency>U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency>
<Country>International</Country>
</Grant>
<Grant><GrantID>R21 AI126361</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01HD090927</GrantID>
<Agency>U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</Agency>
<Country>International</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Nat Nanotechnol</MedlineTA>
<NlmUniqueID>101283273</NlmUniqueID>
<ISSNLinking>1748-3387</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D050997" MajorTopicYN="N">Nanomedicine</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014771" MajorTopicYN="N">Virion</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>3</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>4</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>3</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32203437</ArticleId>
<ArticleId IdType="doi">10.1038/s41565-020-0674-9</ArticleId>
<ArticleId IdType="pii">10.1038/s41565-020-0674-9</ArticleId>
<ArticleId IdType="pmc">PMC7094976</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Gao, J., Tian, Z. & Yang, X. Biosci. Trends https://doi.org/10.5582/bst.2020.01047 (2020).</Citation>
</Reference>
<Reference><Citation>Wang, M. et al. Cell Res. 30, 269–271 (2020).</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0282-0</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhu, N. et al. N. Engl. J. Med. 382, 727–733 (2020).</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Haladyj, E., Sikora, M., Felis-Giemza, A. & Olesinska, M. Reumatologia 56, 164–173 (2018).</Citation>
<ArticleIdList><ArticleId IdType="doi">10.5114/reum.2018.76904</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Savarino, A., Boelaert, J. R., Cassone, A., Majori, G. & Cauda, R. Lancet Infect. Dis. 3, 722–727 (2003).</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(03)00806-5</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Keyaerts, E. et al. Antimicrob. Agents Chemother. 53, 3416–3421 (2009).</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01509-08</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vincent, M. J. et al. Virol. J. 2, 69 (2005).</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-2-69</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hempelmann, E. Parasitol. Res. 100, 671–676 (2007).</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1007/s00436-006-0313-x</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pelt, J. et al. Pharmacol. Ther. 191, 43–49 (2018).</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2018.06.007</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Wolfram, J. et al. Sci Rep 7, 13738 (2017).</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-14221-2</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Miller, S. E. et al. Dev. Cell 33, 163–175 (2015).</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2015.03.002</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Wolfram, J. & Ferrari, M. Nano Today 25, 85–89 (2019).</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1016/j.nantod.2019.02.005</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gentile, E. et al. Future Oncol. 9, 1849–1859 (2013).</Citation>
<ArticleIdList><ArticleId IdType="doi">10.2217/fon.13.146</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Wu, K., Li, W., Peng, G. & Li, F. Proc. Natl Acad. Sci. USA 106, 19970–19974 (2009).</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0908837106</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Li, W. et al. Nature 426, 450–454 (2003).</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1038/nature02145</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Wang, H. et al. Cell Res. 18, 290–301 (2008).</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1038/cr.2008.15</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Inoue, Y. et al. J. Virol. 81, 8722–8729 (2007).</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00253-07</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Wrapp, D. et al. Science 367, 1260–1263 (2020).</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1126/science.abb2507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Yao, X. et al. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa237 (2020).</Citation>
</Reference>
<Reference><Citation>Liu, J. et al. Cell Discov. 6, 16 (2020).</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1038/s41421-020-0156-0</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Dowall, S. D. et al. J. Gen. Virol. 96, 3484–3492 (2015).</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.000309</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Madrid, P. B. et al. PLoS One 8, e60579 (2013).</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0060579</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Roques, P. et al. Viruses 10, 268 (2018).</Citation>
<ArticleIdList><ArticleId IdType="doi">10.3390/v10050268</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A55 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001A55 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Curation |type= RBID |clé= pubmed:32203437 |texte= Insights from nanomedicine into chloroquine efficacy against COVID-19. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:32203437" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
![]() | This area was generated with Dilib version V0.6.38. | ![]() |